<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516826</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01-055</org_study_id>
    <nct_id>NCT02516826</nct_id>
  </id_info>
  <brief_title>The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease</brief_title>
  <official_title>The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease by Smart Angioplasty Research Team: SMART-ROAD Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Stains have demonstrated consistent benefits to reduce cardiovascular events in several
           primary and secondary prevention trials. The suppression of plaque progression or
           regression may be a part of mechanism of clinical benefit. The intravascular ultrasound
           studies demonstrated that intensive statin therapy can regress or inhibit the
           progression of coronary atherosclerosis.

        2. Unregulated renin-angiotensin system is important in the pathogenesis of cardiovascular
           disease. Angiotensin receptor antagonists (ARB) have been reported to improve clinical
           outcomes in patients with heart failure, left ventricular dysfunction, myocardial
           infarction, and high-risk patients. Several small studies showed that ARBs were
           effective to inhibit the progression of coronary atherosclerosis by intravascular
           ultrasound examination.

        3. The combined therapy with statins and ARBs may be additive or synergistic effects on the
           atherosclerosis regression as well as to improve endothelial dysfunction and insulin
           resistance in addition to lowering cholesterol levels and blood pressure when compared
           with either monotherapy in patients.

        4. Serial computed tomography angiography (CTA) can be utilized to assess the effect of
           treatment on coronary plaque morphology. In addition to the assessment of luminal
           stenosis, CTA also allows characterization of plaque morphology.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PAV(nominal change of percent atheroma volume) in the proximal to mid segments of major epicardial coronary arteries</measure>
    <time_frame>Over the 48weeks</time_frame>
    <description>Left main, LAD proximal to mid (from ostium to a large second diagonal branch), LCX proximal (from ostium to a large first obtuse marginal branch), RCA (from ostium to a distal bifurcation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TAV (nominal change of total atheroma volume) in the proximal to mid segments of major epicardial coronary arteries</measure>
    <time_frame>Over the 48weeks</time_frame>
    <description>Left main, LAD proximal to mid (from ostium to a large second diagonal branch), LCX proximal (from ostium to a large first obtuse marginal branch), RCA (from ostium to a distal bifurcation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LAPV (nominal change of percent low attenuation plaque volume)</measure>
    <time_frame>Over the 48weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nominal change of atheroma volume in 10 mm subsegment with greatest disease severity</measure>
    <time_frame>Over the 48weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance</measure>
    <time_frame>Over the 48weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>Over the 48weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">504</enrollment>
  <condition>Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10mg in combination with placebo of Olmesartan 20mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan 20mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan/Rosuvastatin(Combination) 20/10mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Rosuvastatin Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <arm_group_label>Olmesartan Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination</intervention_name>
    <description>Rosuvastatin/Olmesartan(Combination)</description>
    <arm_group_label>Combination Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Rosuvastatin</intervention_name>
    <arm_group_label>Olmesartan Arm</arm_group_label>
    <arm_group_label>Combination Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Olmesartan</intervention_name>
    <arm_group_label>Rosuvastatin Arm</arm_group_label>
    <arm_group_label>Combination Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Rosuvastatin/Olmesartan(Combination)</intervention_name>
    <arm_group_label>Rosuvastatin Arm</arm_group_label>
    <arm_group_label>Olmesartan Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be at 19 years~70 years of age

          2. Patients undergoing coronary CTA with coronary artery stenosis 30~70%

          3. Informed consent

          4. Appropriate CT resolution enough to measure of plaque volume

          5. Patients who are stain and renin-angiotensin system blocker na√Øve at least for 1 year

        Exclusion Criteria:

          1. Patients with&gt;=70% luminal stenosis or requiring percutaneous coronary
             intervention(PCI)

          2. Severely calcifiedcoronary artery

          3. Patients who have a history of previous PCI or coronary artery bypass grafting
             surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center,Seoul,Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyeon-Cheol Gwon, PhD</last_name>
    <phone>2-3410-3418</phone>
    <phone_ext>82</phone_ext>
    <email>hcqwon@skku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Bin Song, PhD</last_name>
    <phone>2-3410-3419</phone>
    <phone_ext>82</phone_ext>
    <email>yoingbin.song@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiac and Vascular Center; Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Hyeon-Cheol Gwon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

